Correlation between neutrophils-to-lymphocyte ratio and soluble FMS-like tyrosine kinase 1 in pregnant women with preeclampsia

Kiki Rizki Amelia, Efendi Lukas, Nurbani Bangsawan,
Isharyah Sunarno, Retno Budiarti Farid, Sriwijaya Qadar

Department of Obstetrics and Gynecology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Correspondence: Kiki Rizki Amelia, Department of Obstetrics and Gynecology, Faculty of Medicine, Hasanuddin University, Perintis Kemerdekaan KM. 10, 90245, Makassar, Indonesia.
Tel.: +62 81292978857.
E-mail: krameliaaa@gmail.com

Key words: neutrophils-to-lymphocyte ratio, soluble FMS-like tyrosine 1, preeclampsia.

Contributions: all authors contributed equally to the manuscript and read and approved the final version of the manuscript.

Conflict of interest: the authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Ethics approval and consent to participate: this study was approved by the Research Ethics Commission of the Faculty of Medicine, Hasanuddin University (No: 814/UN4.6.4.5.31/PP36/202).

Informed consent: all patients were informed about the study's objectives, procedures, potential risks, and benefits, and they voluntarily agreed to participate by providing written informed consent.

Patient consent for publication: obtained

Availability of data and materials: data and materials are available from the corresponding author upon request.

Abstract

Preeclampsia (PE) is a multi-system syndrome in pregnancy that affects 5-10% of pregnancies and is a significant cause of perinatal morbidity and mortality. Therefore, an early and precise diagnosis of PE is needed. Several biomarkers have been used for this diagnosis. The neutrophil-to-lymphocyte ratio (NLR) is a potential biomarker that can be assessed through routine blood tests, but few studies have been conducted to compare NLR with other conventional markers. This study analyzes the correlation between NLR and soluble FMS-like tyrosine kinase 1 (sFLT-1) levels in pregnant women with PE.

This study used a cross-sectional study among 88 patients divided into two groups (normal n=44, PE n=44) by consecutive sampling. All research subjects took venous blood samples and performed routine blood tests and sFLT-1. All statistical analyses were performed using the Statistical Program for Social Sciences (IBM SPSS 24, Chicago, IL, USA). There was no significant difference between the NLR in the control and PE groups, which were 5.45 (0.5) and 5.87 (5.5), respectively. The sFLT-1 marker increased significantly and increased in normal pregnancy and PE, namely 6336 (579) pg/mL and 18,775 (9841) pg/mL. NLR and log sFLT-1 were not correlated in PE (rho=0.11, p=0.451), but they were related in normal pregnancy (rho=0.705, p<0.001).

In conclusion, there is a difference in sFLT-1 levels in PE and controls but no difference in the NLR biomarker. NLR does not correlate with the sFLT-1 biomarker.

Introduction

Preeclampsia (PE) is a dangerous pregnancy-related disorder that affects 5-10% of pregnancies worldwide, contributing significantly to maternal and perinatal morbidity and mortality.[1] It is characterized by high blood pressure and signs of organ damage, often affecting the liver and kidneys.[2] The early detection of PE is crucial to mitigate severe outcomes such as eclampsia and premature birth, which can lead to maternal and neonatal death.[3,4]

The neutrophil-to-lymphocyte ratio (NLR) is emerging as a cost-effective biomarker for PE due to its availability through routine blood tests. Studies have shown that NLR is significantly elevated in women with PE, suggesting a heightened inflammatory response associated with the condition. Elevated levels of soluble FMS-like tyrosine kinase 1 (sFLT-1), a protein linked to anti-angiogenic processes, have also been associated with PE. The correlation between elevated sFLT-1 and increased NLR suggests a possible interaction between inflammatory and anti-angiogenic pathways in the development of PE.[5-8]

If a significant correlation between NLR and sFLT-1 is confirmed, it could support the use of NLR as a simple, inexpensive predictive marker for PE. This study aims to explore this relationship, which could pave the way for improved early diagnosis and better clinical management of PE, ultimately reducing the risks of severe maternal and fetal outcomes.

Materials and Methods
Subjects and data collections

A cross-sectional study was conducted on 88 pregnant women, divided into two groups (normal pregnancy n=44; PE n=44) in Dr. Wahidin Sudirohusodo Hospital, Makassar, South Sulawesi, Indonesia. This study was approved by the Research Ethics Commission of the Faculty of Medicine, Hasanuddin University (No: 814/UN4.6.4.5.31/PP36/202).

Results

The mean age and gestational age in this study were 30.08 (5.96) years and 37.6 (0.22) weeks (Table 1). There was no significant difference between the NLR in the control and PE groups, which were 5.45 (0.5) and 5.87 (5.5), p=0.455. The sFLT-1 marker significantly increased and increased in normal pregnancy and PE, namely 6336 (579) pg/mL and 18775 (9841) pg/mL with p<0.001. NLR and log sFLT-1 were not correlated in PE (rho=0.11, p=0.451) but they were related in normal pregnancy (rho=0.705, p<0.001) (Table 2, Figures 1 and 2).

Discussion

The increase in NLR in PE is driven by placental hypoxia and oxidative stress, which trigger systemic inflammation through neutrophil activation, the release of pro-inflammatory cytokines such as interleukin (IL)-1β and IL-18, and NLRP3 inflammasome activation, with potential therapeutic regulation *via* increased *miR-135* or reduced *PCSK6*.[9,10] NLR is significantly higher in preeclamptic patients compared to normal pregnancies, serving as a marker of inflammatory sensitivity and a predictor of disease severity, including distinguishing mild from severe cases.[5,11] Furthermore, placental hypoxia and neutrophil activation produce microvesicles that exacerbate endothelial dysfunction, reinforcing inflammatory mechanisms in PE.[12,13]

Although NLR is often elevated, some studies have shown its diagnostic value as insignificant. This variation may be attributed to the heterogeneity of patient groups, differences in blood sample collection times, and other factors such as infections or non-obstetric complications affecting systemic inflammation. Additionally, in mild PE, inflammation may be lower than in its severe form, reducing the differences in NLR compared to normal pregnancies.[14,15] These differences may also be caused by fluctuating levels of hormones or cytokines during pregnancy, which are not always directly correlated with the severity of PE.[7]

The significant increase in sFLT-1 levels in PE is primarily driven by placental hypoxia and oxidative stress, which trigger the overexpression of anti-angiogenic factors. sFLT-1 binds to

vascular endothelial growth factor (VEGF) and placental growth factor, sequestering them and impairing angiogenesis, leading to endothelial dysfunction and maternal hypertension.[16,17] Elevated sFLT-1 disrupts vascular remodeling by limiting trophoblast invasion into maternal spiral arteries, exacerbating placental ischemia, and perpetuating the cycle of anti-angiogenic dominance.[18,19] This imbalance in angiogenic factors correlates with disease severity and maternal organ dysfunction, making sFLT-1 a reliable biomarker for identifying high-risk preeclamptic pregnancies.[20,21]

Studies have confirmed that sFLT-1 levels are significantly higher in PE compared to normal pregnancies, and this elevation is particularly pronounced in severe and early-onset cases.[22,23] For example, a study demonstrated that sFLT-1 levels above a certain threshold predict adverse maternal and fetal outcomes with high sensitivity and specificity, solidifying its role in clinical risk stratification.[24,25]

The lack of correlation between NLR and sFLT-1 levels may stem from their differing mechanistic roles in PE. sFLT-1 levels are primarily driven by placental hypoxia and the release of antiangiogenic factors like VEGF receptor decoys, which impair vascular endothelial repair and promote hypertension.[16,17] Meanwhile, NLR reflects systemic inflammation through neutrophil activation and lymphocyte suppression, processes influenced by systemic rather than localized placental factors.[18,25] Additionally, PE's heterogeneous presentation means that sFLT-1 levels may be elevated even in cases without significant systemic inflammation, reducing the correlation between NLR and sFLT-1.[26]

The strong correlation between NLR and sFLT-1 in normal pregnancies likely reflects a coordinated physiological response. As gestation progresses, the gradual rise in sFLT-1 contributes to subtle shifts in maternal vascular dynamics and may trigger mild inflammatory responses, evidenced by increased NLR.[27,28] Unlike PE, where inflammation is often decoupled from angiogenic dysregulation, normal pregnancies balance angiogenic and inflammatory signals, leading to a proportional relationship.[22,29] This connection suggests a more integrated regulatory mechanism in normal pregnancies compared to the pathological disruptions observed in PE.[30,31]

Conclusions

The increase in sFLT-1 and the increase in NLR are correlated under normal pregnancy. There is a difference in sFLT-1 levels in PE and controls but no difference in the biomarker NLR. NLR does not correlate with the biomarker sFLT-1.

References

1. Ali M, Ahmed M, Memon M, et al. Preeclampsia: a comprehensive review. Clin Chim Acta 2024;563:119922.
2. Fox R, Kitt J, Leeson P, et al. Preeclampsia: risk factors, diagnosis, management, and the cardiovascular impact on the offspring. J Clin Med 2019;8:1625.
3. Kahramanoglu Ö, Schiattarella A, Demirci O, et al. Preeclampsia: state of art and future perspectives. A special focus on possible preventions. J Obstet Gynaecol 2022;42:766-77.
4. Boutin A, Guerby P, Gasse C, et al. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study. Am J Obstet Gynecol 2021;224:204.e1-e7.
5. Kang Q, Li W, Yu N, et al. Predictive role of neutrophil-to-lymphocyte ratio in preeclampsia: a meta-analysis including 3982 patients. Pregnancy Hypertens 2020;20:111-8.
6. Nguyen TH, Bui T, Vo T, et al. Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam. Pregnancy Hypertens 2018;14:37-42.
7. Mannaerts D, Heyvaert S, De Cordt C, et al. Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? J Matern Fetal Neonatal Med 2019;32:1412-9.

8. Acharya N, Mohammad S, Mohammad S, et al. Neutrophil-lymphocyte ratio as a bio-inflammatory prognostic marker of fetomaternal outcomes of preeclampsia: a narrative review. J Pharm Res Int 2021;33:1-8.
9. Cheng SB, Nakashima A, Huber WJ, et al. Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors. Cell Death Dis 2019;10:927.
10. Zhao X, Zhang X, Wu Z, et al. Up-regulation of microRNA-135 or silencing of PCSK6 attenuates inflammatory response in preeclampsia by restricting NLRP3 inflammasome. Mol Med 2021;27:82.
11. Wang J, Zhu QW, Cheng XY, et al. Assessment efficacy of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in preeclampsia. J Reprod Immunol 2019;132:29-34.
12. Chiang YT, Seow KM, Chen KH. The pathophysiological, genetic, and hormonal changes in preeclampsia: a systematic review of the molecular mechanisms. Int J Mol Sci 2024;25:4532.
13. Ye D, Li S, Ma Z, et al. Diagnostic value of platelet to lymphocyte ratio in preeclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2023;36:2234540.
14. Biswas M, Belle VS, Maripini N, Prabhu K. Neutrophil-lymphocyte ratio in pregnancy-associated maternal complications: a review. Asian Pac J Reprod 2021;10:252-61.
15. Mohamed RA, Ali IA. Role of neutrophil / lymphocyte ratio, uric acid / albumin ratio and uric acid / creatinine ratio as predictors to severity of preeclampsia. BMC Pregnancy Childbirth 2023;23:763.
16. Dröge LA, Perschel FH, Stütz N, et al. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study. Hypertension 2021;77:461-71.
17. Gaccioli F, Sovio U, Gong S, et al. Increased placental sFLT1 (soluble fms-like tyrosine kinase receptor-1) drives the antiangiogenic profile of maternal serum preceding preeclampsia but not fetal growth restriction. Hypertension 2022;80:325-34.
18. Biwer LA, Man JJ, Ulzurrun JFI, et al. Prior Sflt1 induced preeclampsia exacerbates post-partum hypertension-mediated aortic stiffness and hypercholesterolemia-induced atherosclerotic inflammation. Hypertension 2023;80:A023.
19. Tasta O, Parant O, Hamdi S, et al. Evaluation of the prognostic value of the sFlt-1/PlGF ratio in early-onset preeclampsia. Am J Perinatol 2020;38:292-8.
20. Miller JJ, Higgins V, Melamed N, et al. Clinical validation of the sFlt-1:PlGF ratio as a biomarker for preeclampsia diagnosis in a high-risk obstetrics unit. J Appl Lab Med 2023;8:457-68.
21. Ohkuchi A, Saito S, Yamamoto T, et al. Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study. Hypertens Res 2021;44:813-21.
22. Nikuei P, Rajaei M, Roozbeh N, et al. Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia. BMC Pregnancy Childbirth 2020;20:80.
23. Park Y, Kim Y, Kim HY, et al. Serum sFlt-1, cystatin C and cathepsin B are potential severity markers in preeclampsia: a pilot study. Arch Gynecol Obstet 2020;301:955-62.
24. Aminuddin NA, Sutan R, Mahdy Z, et al. The feasibility of soluble Fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia. PLoS One 2022;17:e0265080.
25. Walentowicz-Sadlecka M, Domaracki P, Sadlecki P, et al. Assessment of the SFlt-1 and sFlt-1/25(OH)D ratio as a diagnostic tool in gestational hypertension (GH), preeclampsia (PE), and gestational diabetes mellitus (GDM). Dis Markers 2019;2019:5870239.
26. Mayer-Pickel K, Kolovetsiou-Kreiner V, Stern C, et al. Effect of low-dose aspirin on soluble FMS-like tyrosine kinase 1/placental growth factor (sFlt-1/PlGF ratio) in pregnancies at high risk for the development of preeclampsia. J Clin Med 2019;8:1429.

27. Lou W, Jiang F, Hu J, et al. Maternal serum angiogenic factor sFlt-1 to PlGF ratio in preeclampsia: a useful marker for differential diagnosis and prognosis evaluation in chinese women. Dis Markers 2019;2019:6270187.
28. Raio L, Bersinger N, Malek A, et al. Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia: a pilot study. J Hypertens 2019;37:1012-7.
29. Pant V, Yadav B, Sharma J. A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth 2019;19:266.
30. Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta. Biomolecules 2020;10:953.
31. Simón E, Herraiz I, Villalaín C, et al. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: a case-control study. Pregnancy Hypertens 2020;20:44-9.

Table 1. Subjects' characteristics.

Variable	Normal n (%)	Preeclampsia n (%)
Age		
Low risk	42 (47.7)	23 (26.1)
High risk	2 (2.3)	21 (23.9)
Gestational age		
Preterm	0 (0.0)	31 (35.2)
Aterm	44 (50.0)	13 (14.8)
Body mass index		
<24.9 kg/m^2	8 (9.1)	0 (0.0)
≥24.9 kg/m^2	35 (41.0)	44 (50.0)
Parity		
Primigravida	14 (15.9)	10 (11.4)
Multigravida	30 (35.1)	34 (38.6)

Table 2. Neutrophil-to-lymphocyte ratio and soluble FMS-like tyrosine kinase 1 among subjects

Variable	Normal, mean (SD)	Preeclampsia, mean (SD)	p
NLR	5.45 (0.5)	5.87 (5.5)	0.455
sFLT-1, pg/mL	6336 (579)	18775.38 (9481)	**<0.001**

Mann Whitney, bold significant. SD, standard deviation; NLR, neutrophil-to-lymphocyte ratio; sFLT-1, soluble FMS-like tyrosine kinase 1.


Figure 1. Neutrophil-to-lymphocyte ratio correlation with soluble FMS-like tyrosine kinase 1 in normal pregnancy (rho=0.705, p<0.001).


Figure 2. Neutrophil-to-lymphocyte ratio correlation with soluble FMS-like tyrosine kinase 1 in preeclampsia (rho=0.117, p=0.451).